JR11 - Conference - Salim MEGAT

JR11 - Conference - Salim MEGAT

by Salim MEGAT

Life & Natural Systems Physics PHPhysicsPHRRelativity physics
🎙 Salim MEGAT 👥 1K 📅 January 28, 2026 ⏱ 36 min 👁 9 📄 conference presentation 🧭 2026-08-16
Available in: English (current) Français

Keywords

ALSmulti-omicsgeneticsTDP-43FUS

Summary

In this conference talk, Salim MEGAT presents his research on amyotrophic lateral sclerosis (ALS) using cross-species multi-omic approaches to identify disease modifiers and new genes. He begins by discussing the genetic architecture of ALS, noting that known genes explain only a third of cases, and uses linkage disequilibrium score regression to show that ALS genetic risk is enriched in excitatory neurons. He then integrates single-cell RNA sequencing data from human motor cortex and mouse models to identify vulnerable cell populations, particularly layer 5 cortical spinal neurons. Through weighted gene co-expression network analysis, he identifies a master regulator, CREB3, which is upregulated in these neurons and shows genetic enrichment. A burden test reveals a rare variant in CREB3 (R119G) that is associated with reduced ALS risk and slower disease progression, and functional studies suggest a gain-of-function mechanism. In the second part, he focuses on FUS mutations and cognitive impairment, using a mouse model with FUS mislocalization. Co-expression analysis identifies a conserved gene module downregulated in ALS and FTLD, which is dependent on TDP-43 and FUS. This module is enriched for ALS genetic risk and correlates with cognitive impairment in patients. He concludes that this approach can prioritize disease modifiers and potential therapeutic targets.

202 words

Critical Evaluation

Value of the Information & Strength of the Argument

The presentation provides valuable insights into the genetic and transcriptomic basis of ALS, integrating multiple data types and species to prioritize novel genes and pathways. The argumentation is solid, as the speaker systematically builds from genetic architecture to cell-type enrichment, then to functional validation, and finally to clinical correlation. The use of cross-species conservation and replication in independent datasets strengthens the conclusions. The identification of CREB3 as a protective factor is particularly compelling, with evidence from rare variant analysis, functional assays, and survival data. The discussion of the FUS-related module and its link to cognitive impairment is also well-supported by transcriptomic and pathological data. The speaker acknowledges limitations, such as sample size and power issues, which adds to the credibility.

Scientific Rigor, Source Quality, Title Accuracy

The presentation demonstrates scientific rigor through the use of multiple datasets, including published single-cell data, whole-genome sequencing cohorts, and functional experiments. The speaker cites specific studies, such as the 2013 Lingal paper on TDP-43 pathology, and mentions replication by independent groups. The title accurately reflects the content, which focuses on cross-species multi-omic approaches. The speaker does not provide explicit citations for all claims, but the context suggests a strong grounding in the literature. The presentation is well-structured and the methods are described in sufficient detail for a scientific audience.

224 words

Title / Content Match

The title accurately reflects the content, which is a conference presentation on cross-species multi-omic approaches to identify disease modifiers and new ALS genes.

Quality & Reliability

8/10

The presentation is based on original research, integrating multi-omic data and genetic analyses, with replication in independent cohorts and functional validation. The speaker is a researcher in the field, and the content is consistent with current scientific knowledge on ALS.

Key Moments

Markers derived by PSI from the transcript: the creator did not define chapters.

Cited Sources

  • Lingal et al. 2013 (TDP-43 pathology) — Mentioned as the source for the 97% TDP-43 aggregation in ALS cases.
  • Al-Chalabi twin study on ALS heritability — Referenced for the 60% heritability estimate.
  • Single-cell RNA-seq datasets from human motor cortex (2021, 2024) — Used for integration with mouse data.
  • Gregory et al. (FUS pathology in ALS) — Mentioned for increased FUS pathology in ALS patients with cognitive impairment.

Concurring Sources

  • Gregory et al. (FUS pathology) — Independent evidence of FUS pathology in ALS with cognitive impairment.
  • Gitler lab (Stanford) findings on CREB3 in motor neurons — Replication of CREB3 overexpression in resilient motor neurons.

Contribution & Novelties

This presentation contributes to the field by demonstrating a cross-species multi-omic approach to identify disease modifiers in ALS, prioritizing novel genes such as CREB3 and a FUS/TDP-43-dependent module. The integration of genetic, transcriptomic, and functional data provides a robust framework for target discovery. The identification of a protective rare variant in CREB3 and its functional validation is a significant advance. The link between a specific gene module and cognitive impairment in ALS offers potential biomarkers and therapeutic targets.

Pour aller plus loin :

  • ALS Genetics — Overview of ALS genetics and associated genes.
  • TDP-43 proteinopathy — Background on TDP-43 pathology in ALS and FTD.
  • Single-cell RNA sequencing — Technique used to profile cell types in this study.

117 words

Radar Profile

The radar profile shows high scores across all dimensions, indicating a well-rounded presentation with strong information content, technical depth, and reliability. The balance between quantity and quality of information is notable, and the technical level is appropriate for a specialized audience.

Reliability 8/10